Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 600 SEK 1.27%
Market Cap: 35.9B SEK

EV/EBITDA
Enterprise Value to EBITDA

34.2
Current
52.3
Median
13
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
34.2
=
Enterprise Value
32.4B SEK
/
EBITDA
949.1m SEK
All Countries
Close
Market Cap EV/EBITDA
SE
Camurus AB
STO:CAMX
35.8B SEK 34.2
US
Eli Lilly and Co
NYSE:LLY
999.6B USD 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
501.2B USD 16.3
CH
Roche Holding AG
SIX:ROG
256.7B CHF 11.6
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 108.3
CH
Novartis AG
SIX:NOVN
206.2B CHF 11.4
US
Merck & Co Inc
NYSE:MRK
250.5B USD 9.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.2
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
142.4B USD 7.4
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 402
34.2
72%
0.5
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
31.4
2-Years Forward
EV/EBITDA
18.7
3-Years Forward
EV/EBITDA
13